Carfilzomib + Carboplatin + Etoposide
Phase 1/2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-Stage Small-Cell Lung Cancer
Conditions
Extensive-Stage Small-Cell Lung Cancer
Trial Timeline
Nov 5, 2013 → May 4, 2017
NCT ID
NCT01987232About Carfilzomib + Carboplatin + Etoposide
Carfilzomib + Carboplatin + Etoposide is a phase 1/2 stage product being developed by Amgen for Extensive-Stage Small-Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01987232. Target conditions include Extensive-Stage Small-Cell Lung Cancer.
What happened to similar drugs?
0 of 7 similar drugs in Extensive-Stage Small-Cell Lung Cancer were approved
Approved (0) Terminated (1) Active (6)
🔄Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)Bristol Myers SquibbPhase 3
🔄BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + EtoposideBristol Myers SquibbPhase 3
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01987232 | Phase 1/2 | Completed |
Competing Products
20 competing products in Extensive-Stage Small-Cell Lung Cancer